| Biomarker ID | 780 |
| PMID | 21993000 |
| Year | 2011 |
| Biomarker | Thiobarbituric acid reactive substances (TBARS) |
| Biomarker Basis | Concentration Based (nmol/ml) |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Upregulated in PCA (without treatment,), PCA (with Treatment: Goserelin A), and PCA (with treatment : Cytoproterone A.) |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Controls Vs PCA (No Treatment) Vs PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) |
| Type of Biomarker | Prognostic |
| Cohort | 50 controls and 50 patients with PCA were chosen for the study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 (Controls Vs PCA (No Treatment) ) & Controls Vs PCA (with Treatment: Goserelin A) & Controls Vs PCA (with Treatment: Cytoproterone A) & PCA (No Treatment) Vs PCA (with Treatment: Cytoproterone A) & PCA (with Treatment: Goserelin A) Vs PCA (with Treatment: Cytoproterone A) |
| Method Used | NA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |